explore -WSS

explore

author：knowledge 2025-09-30 14:58:30 - browse：33968

Verve Therapeutics CEO Sekar Kathiresan Verve

SAN FRANCISCO — The promise of genome editing has given rise to potentially curative medicines for rare, life-threatening diseases that generally affect small numbers of patients. But since Verve Therapeutics was founded in 2018, it’s had a wider aperture: using the molecular tools of genome editing to go after the most common cause of death in the world.

The plan, according to Verve CEO Sekar Kathiresan, is to edit out heart attacks for the millions of people at risk for severe cardiovascular disease. It’s a goal that’s more than a little audacious. There’s just one approved genome editing medicine, a treatment for sickle cell disease, and it only passed Food and Drug Administration review last month. Base editing, the CRISPR successor Verve uses to conduct its molecular surgery, is only a few years old.

“When we started, there were so many things that we were kind of going against the grain on,” Kathiresan told STAT at the J.P. Morgan Healthcare Conference in San Francisco this week. “In 2018, it was all about platforms, not about specific diseases and products, or taking this kind of idea for a large indication as opposed to cancer or rare disease. But we’ve always been motivated by a deep conviction in one simple research insight, which is that if your blood cholesterol is really low, lifelong, it is very hard to get a heart attack.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： White House Covid adviser calls on docs to combat misinformation

WSS

Cell therapy fails to slow type 1 diabetes, but safety is established

Orangutan used medicinal plant to treat wound, first time ever seen

Medical bills so high, Medicare adding extra digits to claim forms

Assistant physicians can help address the primary care shortage

H5N1 bird flu virus started spreading in cows in Texas in December

FTC falls short on scrutinizing hospital mergers, study says

focus

explore

hotspot

In age of alternative facts, a scholarly course on calling out crap

UnitedHealth financials solid despite Change Healthcare cyberattack

In Memoriam: Notable people who died in 2023

People with substance use disorder deserve online privacy

At least 13 dead in Texas as scorching temps continue

'A game

Supreme Court strikes down use of affirmative action

Neurocrine congenital adrenal hyperplasia trial succeeds

Drug repurposing or repositioning? The language matters

Why does health care cost so much? A reading guide

entertainment

More tobacco lobbyists active in statehouses

Cholera vaccine supply gets boost as demand surges globally

White House Covid adviser calls on docs to combat misinformation

Free Covid tests will again be offered to all U.S. households

Close Medicare's dangerous gaps in addiction treatment coverage

People with substance use disorder deserve online privacy

leisure time

focus

knowledge

explore